Multivisceral Resection for Locally Advanced Gastric and Gastroesophageal Junction Cancers—11-Year Experience at a High-Volume North American Center
- 49 Downloads
The oncologic benefit of multivisceral en bloc resections for T4 gastroesophageal tumors has been questioned, given the increased morbidity associated. We thus sought to investigate the surgical and oncologic outcomes of curative-intent en bloc multivisceral resections for T4 gastroesophageal carcinomas.
Between 2005 and 2016, 35 of the 525 patients who had gastric or EGJ carcinomas underwent curative-intent multivisceral resections for direct invasion or adhesion to adjacent organs.
Postoperative complications occurred in 16(46%), 10 of which were Clavien-Dindo ≥ 3 (29%). Ninety-day mortality was 3%. The R0 resection rate was 94% (33). Direct organ invasion (pT4b) was confirmed on pathological analysis in 14 (40%) and did not affect survival. The majority (28, 80%) had lymph node involvement with a high nodal disease burden and was associated with decreased survival. Overall 5-year survival rate was 34%, and the vast majority of recurrences were distant/peritoneal (81%). On multivariate analysis, positive lymph nodes (H.R. 21.2; 95%CI 2.34–192) and R1 resection (H.R. 5.6; 95%CI 1.02–30.9) were predictors of survival.
Multivisceral resections for T4 gastric and GEJ adenocarcinomas, in combination with effective systemic therapy, result in prolonged long-term survival with acceptable morbidity. Complete resection to negative margins should remain a mainstay of curative-intent treatment in carefully selected patients.
KeywordsGastric cancer Locally advanced T4 Surgery
Compliance with Ethical Standards
This study was approved by the McGill University Health Center’s (MUHC) institutional review board.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
- 1.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136(5). https://doi.org/10.1002/ijc.29210.
- 8.Martin RC, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Annals of surgery. 2002;236(2):159–65. https://doi.org/10.1097/01.SLA.0000022023.28027.5C. CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2016;27(suppl 5):v38-v49. https://doi.org/10.1093/annonc/mdw350. CrossRefGoogle Scholar
- 16.Otsuji E, Yamaguchi T, Sawai K, Okamoto K, Takahashi T. Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. British Journal of Cancer. 1999;79(11):1789–93. https://doi.org/10.1038/sj.bjc.6690285.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Kitamura K, Nishida S, Ichikawa D, Taniguchi H, Hagiwara A, Yamaguchi T et al. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. British Journal of Surgery. 1999;86(1):119–22. https://doi.org/10.1046/j.1365-2168.1999.00967.x.CrossRefPubMedGoogle Scholar
- 19.Oñate-Ocaña LF, Becker M, Carrillo JF, Aiello-Crocifoglio V, Gallardo-Rincón D, Brom-Valladares R et al. Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. Journal of Surgical Oncology. 2008;98(5):336–42. https://doi.org/10.1002/jso.21118.CrossRefPubMedGoogle Scholar
- 20.Colen KL, Marcus SG, Newman E, Berman RS, Yee H, Hiotis SP. Multiorgan resection for gastric cancer: intraoperative and computed tomography assessment of locally advanced disease is inaccurate. Journal of Gastrointestinal Surgery. 2004;8(7):897–900. https://doi.org/10.1016/j.gassur.2004.08.005.CrossRefGoogle Scholar
- 25.Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet (London, England). 1996;347(9007):995–9.CrossRefGoogle Scholar
- 26.Al-Batran S-E, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncology. 2017. https://doi.org/10.1001/jamaoncol.2017.0515.
- 27.Serrano OK, Huang K, Ng N, Yang J, Friedmann P, Libutti SK et al. Correlation between preoperative endoscopic ultrasound and surgical pathology staging of gastric adenocarcinoma: A single institution retrospective review. Journal of Surgical Oncology. 2016;113(1):42–5. https://doi.org/10.1002/jso.24098.CrossRefPubMedGoogle Scholar
- 28.Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC et al. Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative. Journal of the American College of Surgeons. 2015;220(1):48–56. https://doi.org/10.1016/j.jamcollsurg.2014.06.023.CrossRefPubMedGoogle Scholar
- 31.Sudarshan M, Alcindor T, Ades S, Aloraini A, van Huyse M, Asselah J et al. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma. Ann Surg Oncol. 2015;22(1):324–30. https://doi.org/10.1245/s10434-014-3875-3.CrossRefPubMedGoogle Scholar
- 32.Kidane B, Coughlin S, Vogt K, Malthaner R. Preoperative chemotherapy for resectable thoracic esophageal cancer. The Cochrane database of systematic reviews. 2015;(5):Cd001556. https://doi.org/10.1002/14651858.CD001556.pub3.
- 33.Ferri LE, Ades S, Alcindor T, Chasen M, Marcus V, Hickeson M et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(6):1512–7. https://doi.org/10.1093/annonc/mdr465. CrossRefGoogle Scholar
- 34.Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(13):1715–21. https://doi.org/10.1200/jco.2010.33.0597. CrossRefGoogle Scholar
- 37.Al-Batran S-E, Homann N, Schmalenberg H, Kopp H-G, Haag GM, Luley KB et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology. 2017;35(15_suppl):4004. https://doi.org/10.1200/JCO.2017.35.15_suppl.4004.Google Scholar
- 38.Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y et al. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. European journal of cancer (Oxford, England: 1990). 2017;79:1–14. https://doi.org/10.1016/j.ejca.2017.03.030. CrossRefGoogle Scholar